Search research articles
Contact Us
Filters
Showing results (71-80 of 135) with videos related to
Page
of 14
Sort By:
British Journal of Clinical Pharmacology
|
February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
Christa E Nath, Judith Trotman, Campbell Tiley, et al.
British Journal of Clinical Pharmacology
|
June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E Nath, Peter J Shaw, Judith Trotman, et al.
Journal of Cancer Survivorship : Research and Practice
|
July 17, 2015
The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study
Allan Ben Smith, Phyllis Butow, Ian Olver, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Irfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
European Urology
|
June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2006
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer
Mark Wong, Rosemary L Balleine, Elaine Y L Blair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles, Se Hoon Park, Claudia Caserta, et al.
BMC Cancer
|
July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
Andrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Journal of the National Cancer Institute
|
July 16, 2010
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial
Peter S Grimison, Martin R Stockler, Damien B Thomson, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 135) with videos related to
Sort By:
Page
of 14
British Journal of Clinical Pharmacology
|
February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
Christa E Nath, Judith Trotman, Campbell Tiley, et al.
British Journal of Clinical Pharmacology
|
June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E Nath, Peter J Shaw, Judith Trotman, et al.
Journal of Cancer Survivorship : Research and Practice
|
July 17, 2015
The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study
Allan Ben Smith, Phyllis Butow, Ian Olver, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Irfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
European Urology
|
June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2006
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer
Mark Wong, Rosemary L Balleine, Elaine Y L Blair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Thomas Powles, Se Hoon Park, Claudia Caserta, et al.
BMC Cancer
|
July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
Andrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Journal of the National Cancer Institute
|
July 16, 2010
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial
Peter S Grimison, Martin R Stockler, Damien B Thomson, et al.
Page
of 14